UCLA Intramural Parkinson’s Disease Research Symposium

Wednesday, July 8, 2020 - 12:00pm


Tuesday, July 7 @ 1:00 pm | Wednesday, July 8 @ 12:00 pm | Friday, July 17 @ 12:00 pm

This intramural symposium was designed to bring UCLA Parkinson’s disease (PD) researchers together to further synergize our efforts and make an even greater impact on PD. The event was originally designed as an in-person symposium but will now be held virtually over three days. We invite you to join us.

For non-speaker participants, please register using this link:

Guest Registration

Webinar links will be provided upon registration.
For questions, please contact Nader Pouratian, MD, PhD at NPouratian@mednet.ucla.edu


EPIDEMIOLOGY, TOXICOLOGY, AND GENETICS
Wednesday, July 8, 2020 | 12:00 pm – 2:30 pm

12:00 p.m. Welcome
12:05 p.m. Cynthia Kusters, MD, PhD
Genetic risk scores and Parkinson's disease
12:20 p.m. Chao Peng, PhD
Transmission and conformational diversity of pathological alpha-synuclein
12:35 p.m. Elizabeth Videlock, MD, PhD
Altered gene expression in the colon of young mice overexpressing alpha-synuclein
12:50 p.m. Discussion/Break
1:05 p.m. Jeff Bronstein, MD, PhD
Studying Environmental Risk Factors in PD using Zebrafish
1:20 p.m. Beate Ritz, MD, PhD
Risk factor and predictors of progression in Parkinson’s disease: a population-based study of patients living in Central California
1:35 p.m. Allan Wu, MD
The California Parkinson’s disease registry and learning healthcare systems
1:50 p.m. Kimberly Paul, PhD
DNA methylation aging and Parkinson’s disease in the PEG study
2:05 p.m. Discussion/Break
2:30 p.m. End

MOLECULAR NEUROSCIENCE AND PHARMACOLOGY
Friday, July 17, 2020 | 12:00 pm – 2:30 pm

12:00 p.m. Welcome
12:05 p.m. Jose Rodriguez, PhD
Probing the origin and spread of synuclein amyloids through structure-activity relationships
12:20 p.m. Gal Bitan, PhD
α-Synuclein in CNS derived exosomes distinguishes Parkinson’s disease from multiple system atrophy
12:35 p.m. Ming Guo, MD, PhD
Making Mitochondria Great Again - Mutations in PINK1 and Parkin
12:50 p.m. Discussion/Break
1:05 p.m. Wael El-Nachef, MD, PhD
The “Second Brain” and Parkinson’s Disease
1:20 p.m. Lin Jiang, PhD
Exploring the structure and pathogenic action of alpha-synuclein fibrils in PD
1:35 p.m. Varghese John, PhD
Neutral sphingomyelinase 2 as a novel target for PD therapeutics development
1:50 p.m. Sally Frautschy, PhD
Potential of aSyn-fibril-structure-based peptide inhibitor liganded to nanoparticles (LMNPs) as a MRI-based Biomarker and therapy for Parkinson’s Disease (PD)
2:05 p.m. Discussion/Break
2:30 p.m. End